← Back to Screener
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX)
Price$18.09
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (4W)-33.66%
VGM Score10.42
Market Capitalization$573.94M
All Metrics
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-30.80%
10-Day Avg Trading Volume0.36M
EPS (Annual)$-4.78
ROI (Annual)-57.77%
Cash / Share (Quarterly)$8.24
ROA (Last FY)-50.25%
Cash Flow / Share (Annual)$-4.12
P/B Ratio2.23x
Net Income / Employee (Annual)$-1,597,000
EPS Incl Extra (Annual)$-4.78
Current Ratio (Annual)10.20x
Quick Ratio (Quarterly)8.65x
3-Month Avg Trading Volume0.38M
52-Week High$26.80
EPS Excl Extra (Annual)$-4.78
Quick Ratio (Annual)10.05x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.74x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.97
ROE (Last FY)-57.77%
EPS Basic Excl Extra (Annual)$-4.78
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return-16.00%
5-Day Price Return-7.10%
EPS Normalized (Annual)$-4.78
Month-to-Date Return-31.41%
EBITD / Share (Annual)$-5.14
Beta0.03x
52-Week Low$14.79
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
May 2026
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics, Inc. Ordinary Shares | — | — | F | $18.09 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.